Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Influenza vaccination of HIV‐1‐positive and hiv‐1‐negative former intravenous drug users

Influenza vaccination of HIV‐1‐positive and hiv‐1‐negative former intravenous drug users The immunogenicity of an anti‐influenza vaccine was assessed in 409 former intravenous drug user volunteers and its effect on the levels of HIV‐1 RNA, proviral DNA and on CD4+ lymphocyte counts in a subset HIV‐1‐positive subjects was measured. HIV‐1‐positive individuals (n = 72) were divided into three groups on the basis of their CD4+ lymphocyte counts, while the 337 HIV‐1‐negative participants were allocated into group four. Haemagglutination inhibiting (HI) responses varied from 45.8 to 70% in the HIV‐1‐positive subjects and were significantly higher in group four (80.7% responses to the H1N1 strain, 81.6% to the H3N2 strain, and 83% to the B strain). The percentage of subjects with HI protective antibody titres (≥ 1:40) increased significantly after vaccination, especially in HIV‐1 uninfected subjects. Immunization caused no significant changes in CD4+ counts and in neither plasma HIV‐1 RNA nor proviral DNA levels. Therefore, vaccination against influenza may benefit persons infected by HIV‐1. J. Med. Virol. 65:644–648, 2001. © 2001 Wiley‐Liss, Inc. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Medical Virology Wiley

Loading next page...
 
/lp/wiley/influenza-vaccination-of-hiv-1-positive-and-hiv-1-negative-former-cTX00kqsi0

References (35)

Publisher
Wiley
Copyright
Copyright © 2001 Wiley Subscription Services
ISSN
0146-6615
eISSN
1096-9071
DOI
10.1002/jmv.2085
Publisher site
See Article on Publisher Site

Abstract

The immunogenicity of an anti‐influenza vaccine was assessed in 409 former intravenous drug user volunteers and its effect on the levels of HIV‐1 RNA, proviral DNA and on CD4+ lymphocyte counts in a subset HIV‐1‐positive subjects was measured. HIV‐1‐positive individuals (n = 72) were divided into three groups on the basis of their CD4+ lymphocyte counts, while the 337 HIV‐1‐negative participants were allocated into group four. Haemagglutination inhibiting (HI) responses varied from 45.8 to 70% in the HIV‐1‐positive subjects and were significantly higher in group four (80.7% responses to the H1N1 strain, 81.6% to the H3N2 strain, and 83% to the B strain). The percentage of subjects with HI protective antibody titres (≥ 1:40) increased significantly after vaccination, especially in HIV‐1 uninfected subjects. Immunization caused no significant changes in CD4+ counts and in neither plasma HIV‐1 RNA nor proviral DNA levels. Therefore, vaccination against influenza may benefit persons infected by HIV‐1. J. Med. Virol. 65:644–648, 2001. © 2001 Wiley‐Liss, Inc.

Journal

Journal of Medical VirologyWiley

Published: Jan 1, 2001

Keywords: ; ; ; ;

There are no references for this article.